475 results on '"Dougan, Stephanie K."'
Search Results
2. Author Correction: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
3. Inhibition of CDK4/6 promotes CD8 T-cell memory formation
4. Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer
5. A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
6. Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy
7. Metabolic modulation of mitochondrial mass during CD4+ T cell activation
8. Immune mechanisms of toxicity from checkpoint inhibitors
9. IFNγ is a central node of cancer immune equilibrium
10. Bicarbonate transport as a vulnerability in pancreatic cancer
11. Leaping toward Tolerance
12. De novo pyrimidine biosynthesis inhibition synergizes with BCL-XLtargeting in pancreatic cancer
13. Antigen identification and high-throughput interaction mapping by reprogramming viral entry
14. Translational advances in pancreatic ductal adenocarcinoma therapy
15. Supplementary Data 1 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
16. Arm B count matrices 4 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
17. Data from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
18. Arm A count matrices 3 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
19. Table S1 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
20. TCR raw data 2 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
21. Transnuclear CD8 T cells specific for the immunodominant epitope Gra6 lower acute‐phase Toxoplasma gondii burden
22. EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer
23. Abstract A093: Deciphering acquired resistance to KRASG12D inhibition in a mouse model of pancreatic ductal adenocarcinoma
24. Abstract A024: B cells facilitate lymph node colonization in pancreatic ductal adenocarcinoma
25. Abstract A066: A novel approach for exocrine pancreas transcriptomics reveals the cellular landscape of the pancreas
26. Abstract B016: Eosinophils alter metastatic spread in pancreatic cancer
27. Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders
28. DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity
29. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
30. Correction: PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
31. Anti–CTLA-4 therapy requires an Fc domain for efficacy
32. CD1d-Restricted pathways in hepatocytes control local natural killer T cell homeostasis and hepatic inflammation
33. Localized CD47 blockade enhances immunotherapy for murine melanoma
34. Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease
35. Cocapture of cognate and bystander antigens can activate autoreactive B cells
36. In vitro flow cytometry assay to assess primary human and mouse macrophage phagocytosis of live cells
37. G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans
38. Abstract SY12-04: Lowering the TCR signaling threshold with a DGKa/z dual inhibitor potentiates anti-tumor immunity
39. Supplementary Figure S6 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
40. Supplemental Figure 1 from Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy
41. Data from Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy
42. Data from Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation
43. Supplemental Figure 2 from Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy
44. Data from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells
45. Supplemental Figure legends from Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy
46. Supplementary Data from Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation
47. Figure S2 from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells
48. Supplemental Figure Legends from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells
49. Data from Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell–Effector Responses
50. Supplemental Figure 3 from Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.